Cancer Genetics, Inc. (CGIX) Starts Presentation at 2nd Annual Marcum MicroCap Conference
Cancer Genetics is a DNA-based cancer diagnostics company servicing some of the most prestigious medical institutions in the world. The company’s tests target hard-to-diagnose cancers such as hematological, urogenital and HPV-associated cancers. CGIX also provides a comprehensive range of non-proprietary oncology-focused tests and laboratory services. The company’s state-of-the-art reference lab is both CLIA certified and CAP accredited and has licensure from several states including New York State. For more information visit the company’s Web site at www.cancergenetics.com
Let us hear your thoughts below:
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in
Marcum MicroCap. Bookmark the
permalink.
